Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 1/20 | 0.54 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.42 |
| ▸ | MAP3K7 | O43318 | 2/20 | 0.41 |
| ▸ | TAB1 | Q15750 | 2/20 | 0.41 |
| ▸ | BTK | Q06187 | 10/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | JAK2 | O60674 | 5/20 | 0.38 |
| ▸ | JAK3 | P52333 | 5/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL157260 | 0.86 | CHEK1 (0.54) | CHEK1NOTUMMAP3K7TAB1BTK | |
| SCHEMBL155227 | 0.86 | CHEK1 (0.54) | CHEK1NOTUMMAP3K7TAB1BTK | |
| SCHEMBL12777831 | 0.85 | MAP3K7 (0.56) | CHEK1NOTUMMAP3K7TAB1BTK | |
| SCHEMBL15631612 | 0.82 | CHEK1 (0.50) | CHEK1NOTUMMAP3K7TAB1BTK | |
| SCHEMBL3224390 | 0.82 | CHEK1 (0.50) | CHEK1MAP3K7TAB1JAK2JAK3 | |
| SCHEMBL3221026 | 0.81 | CHEK1 (0.49) | CHEK1NOTUMMAP3K7TAB1BTK | |
| SCHEMBL16764899 | 0.81 | CHEK1 (0.49) | CHEK1NOTUMMAP3K7TAB1BTK | |
| SCHEMBL2024785 | 0.79 | BTK (0.58) | CHEK1BTK | |
| SCHEMBL28068449 | 0.79 | MAP3K7 (0.47) | CHEK1MAP3K7TAB1CYP3A4JAK2 | |
| SCHEMBL21678729 | 0.77 | CHEK1 (0.45) | CHEK1MAP3K7TAB1BTKJAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9738644-B2 | Chemical compounds, compositions and methods for kinase modulation | INFINITY PHARMACEUTICALS, INC. (US) | 2017-08-22 | — | — | US | disclosed |
| US-9738644-B2 | Chemical compounds, compositions and methods for kinase modulation | INFINITY PHARMACEUTICALS, INC. (US) | 2017-08-22 | — | — | US | disclosed |
| EP-2571357-B1 | CHEMICAL COMPOUNDS, COMPOSITIONS AND METHODS FOR KINASE MODULATION | INFINITY PHARMACEUTICALS INC (US) | 2016-07-06 | — | — | EP | disclosed |
| US-20160016957-A1 | CHEMICAL COMPOUNDS, COMPOSITIONS AND METHODS FOR KINASE MODULATION | INFINITY PHARMACEUTICALS, INC. | 2016-01-21 | — | — | US | disclosed |
| US-20160016957-A1 | CHEMICAL COMPOUNDS, COMPOSITIONS AND METHODS FOR KINASE MODULATION | INFINITY PHARMACEUTICALS, INC. | 2016-01-21 | — | — | US | disclosed |
| US-9181221-B2 | Chemical compounds, compositions and methods for kinase modulation | INFINITY PHARMACEUTICALS, INC. (US) | 2015-11-10 | — | — | US | disclosed |
| US-9181221-B2 | Chemical compounds, compositions and methods for kinase modulation | INFINITY PHARMACEUTICALS, INC. (US) | 2015-11-10 | — | — | US | disclosed |
| US-20140088099-A1 | CHEMICAL COMPOUNDS, COMPOSITIONS AND METHODS FOR KINASE MODULATION | INFINITY PHARMACEUTICALS, INC. (US) | 2014-03-27 | — | — | US | disclosed |
| US-20140088099-A1 | CHEMICAL COMPOUNDS, COMPOSITIONS AND METHODS FOR KINASE MODULATION | INFINITY PHARMACEUTICALS, INC. (US) | 2014-03-27 | — | — | US | disclosed |
| US-20120059000-A1 | CHEMICAL COMPOUNDS, COMPOSITIONS AND METHODS FOR KINASE MODULATION | INFINITY PHARMACEUTICALS, INC. | 2012-03-08 | — | — | US | disclosed |
| US-20120059000-A1 | CHEMICAL COMPOUNDS, COMPOSITIONS AND METHODS FOR KINASE MODULATION | INFINITY PHARMACEUTICALS, INC. | 2012-03-08 | — | — | US | disclosed |
| WO-2011146882-A1 | CHEMICAL COMPOUNDS, COMPOSITIONS AND METHODS FOR KINASE MODULATION | INTELLIKINE, INC. (US) | 2011-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059000-A1 | CHEMICAL COMPOUNDS, COMPOSITIONS AND METHODS FOR KINASE MODULATION | MAP3K13, AKT3, PIK3CA | CHEK1 190/4885NOTUM 3284/4885MAP3K7 23/4885 |
| US-20140088099-A1 | CHEMICAL COMPOUNDS, COMPOSITIONS AND METHODS FOR KINASE MODULATION | MAP3K13, AKT3, PIK3CA | CHEK1 190/4885NOTUM 3284/4885MAP3K7 23/4885 |
| US-20160016957-A1 | CHEMICAL COMPOUNDS, COMPOSITIONS AND METHODS FOR KINASE MODULATION | MAP3K13, AKT3, PIK3CA | CHEK1 190/4885NOTUM 3284/4885MAP3K7 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.